Savara Inc. $SVRA Stock Holdings Cut by Farallon Capital Management LLC

Farallon Capital Management LLC cut its position in shares of Savara Inc. (NASDAQ:SVRA) by 63.4% during the 3rd quarter, Holdings Channel reports. The firm owned 2,500,000 shares of the company’s stock after selling 4,335,000 shares during the period. Farallon Capital Management LLC’s holdings in Savara were worth $8,925,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Prudential Financial Inc. acquired a new stake in shares of Savara in the second quarter valued at $30,000. BNP Paribas Financial Markets grew its holdings in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after acquiring an additional 4,626 shares during the period. Brevan Howard Capital Management LP acquired a new position in Savara during the second quarter worth about $33,000. Russell Investments Group Ltd. raised its position in Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after acquiring an additional 9,463 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new stake in Savara in the second quarter worth about $42,000. Institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on SVRA. Oppenheimer set a $10.00 price objective on shares of Savara in a research report on Tuesday, December 23rd. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a report on Saturday. Guggenheim reissued a “buy” rating on shares of Savara in a research note on Tuesday, December 23rd. UBS Group set a $10.00 target price on shares of Savara in a report on Tuesday, December 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.86.

Savara Trading Down 1.3%

Shares of NASDAQ SVRA opened at $5.25 on Monday. The business has a 50 day simple moving average of $5.67 and a 200 day simple moving average of $4.97. Savara Inc. has a 52 week low of $1.89 and a 52 week high of $7.01. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -9.91 and a beta of 0.31. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.65 and a current ratio of 7.65.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). On average, research analysts predict that Savara Inc. will post -0.45 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.